Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Coluracetam | NSI-189 | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 20-80 mg/day divided into 2-3 doses | 40 mg once daily (for educational context — investigational compound, not approved for any indication) |
| Timing | Morning and early afternoon. Sublingual administration may provide faster onset. With or without food. | Once daily, time of day not definitively established from clinical data. With or without food. |
| Cycle Duration | Cycles of 4-8 weeks on, 2-4 weeks off | Phase 2 trial used 12-week treatment duration. Long-term safety data unavailable. |
| Evidence Level | animal_plus_anecdotal | moderate_human |
Enhances high-affinity choline uptake (HACU) via a unique mechanism distinct from other racetams — it increases HACU even in damaged cholinergic neurons, suggesting a choline uptake enhancement rather than mere stimulation. This HACU enhancement persists even after the compound has been cleared, indicating a lasting modification of choline transporter activity. Also shows affinity for AMPA receptors.
20-80 mg/day divided into 2-3 doses
Morning and early afternoon. Sublingual administration may provide faster onset. With or without food.
Cycles of 4-8 weeks on, 2-4 weeks off
Benzylpiperizine-aminopyridine compound that stimulates neurogenesis of human hippocampus-derived neural stem cells in vitro and increases hippocampal volume in vivo. Mechanism is independent of serotonin or norepinephrine reuptake inhibition — fundamentally distinct from traditional antidepressants. Activates the TrkB receptor (BDNF receptor) and downstream Akt/PI3K signaling pathways to promote synaptic plasticity, long-term potentiation, and neuronal survival. Enhances BDNF expression in hippocampal subregions critical for memory consolidation and mood regulation. Originally developed as ALTO-100 (Alto Neuroscience) for treatment-resistant depression with cognitive impairment.
40 mg once daily (for educational context — investigational compound, not approved for any indication)
Once daily, time of day not definitively established from clinical data. With or without food.
Phase 2 trial used 12-week treatment duration. Long-term safety data unavailable.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →